Justices to Consider Patent Case on ‘Skinny’ Drug Labels (1)

The US Supreme Court will hear generic drug maker Hikma Pharmaceuticals USA Inc.'s challenge of an appeals court holding that ...
STAT

Supreme Court agrees to review ‘skinny labeling’ and generic drug access

The Supreme Court agreed to review a controversy over so-called skinny labels for medicines, a decision that will be closely ...

US Supreme Court to hear 'skinny label' patent fight involving Amarin

The U.S. Supreme Court agreed on Friday to hear a patent dispute involving Amarin Pharma's cardiovascular drug Vascepa that ...
JD Supra

Previewing Generic’s Skinny Label: Supreme Court to Rule on Teva’s Certiorari Petition

Supreme Court set to consider cert. petition on generic drug use of “skinny labels” to avoid infringing method of use patents. Court expected to consider cert. petition during court conference on May ...
JD Supra

Federal Circuit Clarifies Rules for Skinny Labeling for Generics and Biosimilar Companies

Last week, the Federal Circuit decided Amarin Pharma, Inc. v. Hikma Pharmaceuticals USA Inc., 23-1169 (Fed. Cir. June 25, 2024), a case that spotlighted the issues of skinny labeling and induced ...
Washington Examiner

Controversy re-ignites over generic drug label changes

The federal government re-ignited a controversial proposal to give generic drug makers the power to unilaterally update product labels to reflect new safety information, a proposal that drew criticism ...
STAT

Solicitor general urges Supreme Court to review ‘skinny labeling’ and generic drug access

Ed Silverman, a senior writer and Pharmalot columnist at STAT, has been covering the pharmaceutical industry for nearly three decades. He is also the author of the morning Pharmalittle newsletter and ...